Originally published In Press as doi:10.1074/jbc.M006399200 on September 25, 2000
J. Biol. Chem., Vol. 275, Issue 51, 40357-40364, December 22, 2000
Structural Requirements for the Adherence of
Plasmodium falciparum-infected
Erythrocytes to Chondroitin Sulfate Proteoglycans of Human
Placenta*
Abdulnaser
Alkhalil
,
Rajeshwara N.
Achur
,
Manojkumar
Valiyaveettil
,
Christian F.
Ockenhouse§, and
D. Channe
Gowda
¶
From the
Department of Biochemistry and Molecular
Biology, Georgetown University Medical Center, Washington, D. C. 20007 and the § Department of Immunology, Walter Reed Army
Institute of Research, Silver Spring, Maryland 20910
Received for publication, July 19, 2000, and in revised form, September 19, 2000
 |
ABSTRACT |
Plasmodium falciparum infection
during pregnancy results in the accumulation of infected red blood
cells (IRBCs) in the placenta, leading to poor pregnancy outcome. In
the preceding paper (Achur, R.N., Valiyaveettil, M., Alkhalil, A.,
Ockenhouse, C. F., and Gowda, D.C. (2000) J. Biol.
Chem. 275, 40344-40356), we reported that unusually low
sulfated chondroitin sulfate proteoglycans (CSPGs) in the intervillous
spaces of the placenta mediate the IRBC adherence. In this study, we
report the structural requirements for the adherence and the minimum
chondroitin 4-sulfate (C4S) structural motif that supports IRBC
adherence. Partially sulfated C4Ss with varying sulfate contents were
prepared by solvolytic desulfation of a fully sulfated C4S. These and
other nonmodified C4Ss, with different proportions of 4-, 6-, and
nonsulfated disaccharide repeats, were analyzed for inhibition of IRBC
adherence to the placental CSPG. C4Ss containing 30-50% 4-sulfated
and 50-70% nonsulfated disaccharide repeats efficiently inhibited
IRBC adherence; C6S had no inhibitory activity. Oligosaccharides of
varying sizes were prepared by the partial depolymerization of C4Ss
containing varying levels of 4-sulfation, and their ability to inhibit
the IRBC adherence was studied. Oligosaccharides with six or more disaccharide repeats inhibited IRBC adherence to the same level as that
of the intact C4Ss, indicating that a dodecasaccharide is the minimum
structural motif required for optimal IRBC adherence. Of the C4S
dodecasaccharides, only those with two or three sulfate groups per
molecule showed maximum IRBC inhibition. These data define the
structural requirements for the IRBC adherence to placental CSPGs with
implications for the development of therapeutics for maternal malaria.
 |
INTRODUCTION |
Plasmodium falciparum, the deadliest among four species
of malaria parasite that infect man, has developed a mechanism for efficient survival in the host by imparting an adherence property to
infected erythrocytes through the surface expression of antigenic variant proteins (1, 2). Since the host develops an antibody response
against these parasite proteins over a period of time, the parasite
constantly switches to different adherent phenotypes by expressing
proteins with different receptor specificity through the use of its
extensive and diverse var gene repertoire (3-11). Thus, in
pregnant women, P. falciparum exploits the chondroitin 4-sulfate (C4S)1 chains in an
opportunistic manner to colonize in the placenta (12-14), which leads
to poor fetal outcome and severe health problems in the mother
(15-17).
A number of studies have shown that endothelial cell surface adhesion
molecules and C4S can function as receptors for the sequestration of
IRBCs to various organs of the host (13, 18). Although one or more of
the endothelial cell receptors are involved in this process, C4S
specifically mediates the accumulation of IRBCs in the intervillous
spaces of human placenta (12-14). Although in vitro
cultured endothelial cells can express CSPGs on their surfaces, and
thus bind C4S-adherent IRBCs as reported (19, 20, 21), in
vivo, endothelial cells express mainly HSPGs and they either lack
or contain low levels of CSPGs. Thus, C4S-adherent IRBCs are present in
very low levels in individuals other than pregnant women (22, 23). As
shown in the preceding paper (24), the placental intervillous
spaces contain relatively high levels of CSPGs, which can
efficiently bind IRBCs. Apparently, the placenta provides an
opportunity by presenting CSPGs for P. falciparum IRBCs to
selectively accumulate in the intervillous spaces, and thus this
phenotype multiplies to high density, causing maternal malaria.
It is well known that pathogenic microorganisms use
carbohydrate-protein mediated adhesion mechanisms for cell invasion and tissue colonization in the host. A number of bacteria, parasites, and
viruses have been reported to use HS moieties of cell surface HSPGs as
receptors for attachment and/or invasion of host cells (25, 26). In
most cases, the GAG chain structural requirements for adherence have
not been studied, and inhibition by highly charged heparin and lack of
inhibition by CS or DS have been attributed to HS chain-specific
binding (25). Although a question remains as to whether those
observations merely represent nonspecific charge interactions by
heparin, it is increasingly becoming clear that microbes use GAG chains
of host cells for adherence (25-29). Recently, it has been shown that
a heparin dodecasaccharide is involved in Chlamydia
trachomatis attachment and infectivity to the host cells (29).
Compared with the large number of microbes that appear to use HS as
adhesion receptors, the evidence for pathogens exploiting CS or DS
chain-specific binding is scarce (25). Among the microbes that have
been studied so far, only two, a subset of herpes simplex virus (25)
and erythrocytic stage P. falciparum (12-14, 24), are known
to use CS chains of CSPG for adherence and tissue colonization, respectively. Of these, P. falciparum is the only protozoan
microbe for which specific CS chain adherence has been established
(12-14, 19-23, 30).
PGs are macromolecules formed by the attachment of GAG chains to
proteins, and they are ubiquitously present in eukaryotic cells and
tissues, mainly as extracellular or cell surface molecules. PGs play a
key role in several biological functions, including the normal
physiology of cartilage tissues, and in the regulation of biological
processes such as cell migration and proliferation, cell-cell
recognition and adhesion, extracellular matrix organization, cell-matrix and substratum adhesion, and morphogenesis (31-36). PGs
are also involved in mobilizing growth factors, enzymes, cytokines, and
protease inhibitors at the sites where they are secreted, to create
reservoirs for efficient biological interactions and to protect
proteins from proteolytic degradation (33-38). Many of the biological
functions of PGs are mediated by the interactions of specific
structural motifs of GAG chains (31-45), e.g. the binding
of distinct heparin domains by type IV collagen (45), a specific
heparin pentasaccharide by antithrombin III (41), DS hexasaccharide
by heparin cofactor II (46), and heparin dodecasaccharide by chlamydial
protein (29), HS dodecasaccharide by tumor-derived angiomodulin (47),
and as shown in this study, a partially sulfated C4S dodecasaccharide
by intraerythrocytic P. falciparum. The characterization of
the fine structural requirements of GAG for ligand binding in microbial
interactions with the host has implications for understanding these
basic biological processes as well as for pharmacological applications.
GAG chains contribute predominantly to the characteristic properties
and functions of PGs. Structurally, GAGs share a common feature in that
all have a linear, O-sulfated polysaccharide backbone consisting of alternating residues of uronic acid (GlcA in CS, IdoUA in DS, and IdoUA and GlcA in HS and heparin) and
hexosamine (GalNAc in CS and DS, and GlcNAc or
GlcNSO32
in HS and heparin) (31, 32). Thus, C4S and
C6S are made up of -GlcA
1-3GalNAc
1-4 disaccharide repeats with
sulfate groups at O-4 or O-6 of GalNAc,
respectively (31). GAGs in general are extremely heterogeneous with
respect to their size, as well as levels, positions, and distribution
of sulfate groups. C4Ss from different sources vary in distribution of
nonsulfated and 4-sulfated disaccharide repeats, and some may also
contain significant amount of 6-, 2,6-, and 4,6-disulfated units (31).
Therefore, detailed studies using defined CS structures could furnish a
complete understanding of the molecular interactions involved between
C4S and the P. falciparum protein-mediated placental IRBC adherence.
Although the results of several studies suggest that C4S mediates IRBC
adherence to the placenta (12-14), the precise nature of the CS chains
and the structural requirements for the adherence of IRBCs to the
placental CSPGs remain unclear. Previous studies have reported
contradictory information regarding the minimum CS chain length
requirement for IRBC binding (48-50). This could be due to the use of
nonrelevant receptors in those studies. In the preceding paper (24), we
showed that the placental intervillous spaces contain high levels of
CSPGs, and that these are the receptors for placental IRBC adherence.
In this study, we established the IRBC binding specificity to the C4S
chains of the placental CSPGs, determined the minimum CS chain motif
involved, and defined structural requirements for IRBC adherence.
 |
EXPERIMENTAL PROCEDURES |
Materials--
C4S (sturgeon notochord), super special grade C6S
(shark cartilage), C2,6diS (shark cartilage), C4,6diS (squid
cartilage), HS (bovine kidney), chondroitin, Proteus
vulgaris chondroitinase ABC, Flavobacterium heparinum
heparitinase (113 units/mg), and Streptomyces hyalurolyticus
hyaluronidase (2000 turbidity reducing units/mg) were purchased from
Seikagaku America (Falmouth, MA). Ovine testicular hyaluronidase (2160 units/mg) was from ICN Biomedicals. C4Ss (bovine trachea and whale
cartilage), DS (porcine intestinal mucosa), HA (human umbilical cord),
gelatin (300 bloom), and BSA were from Sigma. SYBR green fluorescent
dye was from Molecular Probes (Eugene, OR).
N,O-Bis(trimethylsilyl)acetamide was from Aldrich. RPMI 1640 medium, glutamine, HEPES, p-aminobenzoic
acid, heparin, and Giemsa stain reagents were from Life Technologies, Inc. Human blood and serum were purchased from Interstate Blood Bank
(Memphis, TN). Polystyrene Petri dishes (Falcon 1058) were from
Becton-Dickinson Labware. Dowex 50W-X8, Bio-Gel P-2, and Bio-Gel P-6
were from Bio-Rad.
P. falciparum Cell Culture--
The parasites were cultured in
RPMI 1640 medium supplemented with 25 mM HEPES, 29 mM sodium bicarbonate, 0.005% hypoxanthine, p-aminobenzoic acid (2 mg/liter), gentamycin sulfate (50 mg/liter), 10% O+ human serum using type O Rh+
human red blood cells at 3% hematocrit. The cultures were incubated at
37 °C in an atmosphere of 90% nitrogen, 5% oxygen, and 5% carbon dioxide. Parasites were synchronized as described previously at the
early ring stage with 5% sorbitol for 5 min (51).
Selection of C4S Adherent IRBCs--
The C4S-adherent parasites
(3D7 clone) were originally selected from the NF-54 laboratory strains
by the panning procedure (52). Tissue culture plastic Petri dishes were
coated overnight with a sterile 10 µg/ml solution of bovine trachea
C4S in PBS, pH 7.2, at room temperature in a tissue culture hood, and
then blocked with a 2% sterile solution of BSA in PBS for 1 h.
Synchronized cultures of the parasites with 10-20% parasitemia at the
late trophozoite or mid-schizont stage were harvested, washed two times with RPMI 1640 medium without serum, suspended at 2% hematocrit, layered on C4S-coated Petri dishes, and incubated at room temperature. After 1 h, unbound RBCs were aspirated, plates were washed gently three times with RPMI 1640 medium, and the bound cells were detached by
vigorous pipetting several times with the culture medium. These parasites were cultured, the panning procedure repeated two more times,
and the final isolate designated as the 3D7 clone. The selected IRBCs
adhered at high density to CSPGs of placental intervillous spaces. The
adherent property of IRBCs significantly decreases over a period of
continuous culture; therefore, the parasites were panned every 6-8
weeks on placental CSPG-coated plates.
Enrichment of IRBCs--
The IRBCs were enriched by gelatin
floatation as described by Jensen (53). Briefly, the parasite cultures
with 10-20% parasitemia were harvested at the late trophozoite stage.
The cells were suspended in 0.65% gelatin in PBS, pH 7.2, and
incubated at 37 °C for 20 min. Most uninfected erythrocytes and
infected erythrocytes containing rings and early trophozoites settled
to the bottom, and the IRBCs with mid-stage and late trophozoites
remained in the supernatant. The supernatant was removed, centrifuged,
and the enriched IRBCs (50-70% parasitemia) were washed twice with
sterile PBS, pH 7.2. A 2% suspension of enriched IRBCs was used for
the cytoadherence assays. In some experiments, parasite cultures with
20-25% parasitemia were used without further enrichment.
IRBC Adherence Assay--
The solutions (10-15 µl) of
purified CSPGs in PBS, pH 7.2, were spotted on 150 × 15-mm
plastic Petri dishes and allowed to coat overnight at 4 °C (52). The
spots were then blocked with 20 µl of 2% BSA for 2 h at room
temperature. The spots coated only with PBS (controls) were similarly
blocked with BSA. After aspirating BSA, 15 µl of a 2% suspension of
enriched parasite culture (50-70% parasitemia) in PBS, pH 7.2, was
overlaid on each spot and incubated at room temperature. Uninfected
RBCs layered on CSPG-coated plates were used as separate negative
controls. After 40 min, the dishes were washed three times with PBS, pH 7.2. The bound cells were fixed with 2% glutaraldehyde and stained with either 1% Giemsa or SYBR green fluorescent dye at 1:10,000 dilution of the stock solution as recommended by the supplier. The
bound IRBCs were counted under light or fluorescent microscopy and
photographed. All assays were carried out either in duplicate or triplicate.
Enzyme Treatments in Adhesion Assays--
The CSPG was coated as
circular spots on plastic Petri dishes (3.5 × 1 cm) as described
above, and the entire inside surface was blocked with BSA. The plates
were then incubated for 2 h with 1 ml of chondroitinase ABC (50 milliunits/ml) or testicular hyaluronidase (50 units/ml) at 37 °C,
or heparitinase (20 milliunits/ml) at 43 °C in buffers containing
protease inhibitors as described (54-56). The CSPG-coated plates were
also treated with S. hyalurolyticus hyaluronidase (40 units/ml) at 60 °C for 2 h (57). The plates were washed three
times with PBS, pH 7.2, and IRBC adhesion was assayed as described above.
Cytoadherence Inhibition Assay--
The solutions of
oligosaccharides or polysaccharides at twice the indicated
concentrations in PBS, pH 7.2, were mixed with equal volumes of 4%
suspension of IRBCs in PBS, pH 7.2, in 96-well microtiter plates. The
suspensions were incubated at room temperature for 30 min with
intermittent mixing, and then layered on CSPG-coated spots on Petri
dishes. After 40 min at room temperature, the unbound cells were washed
and the bound cells were fixed with 2% glutaraldehyde, stained with
either Giemsa reagent or SYBR green, and measured as outlined above.
Preparation of Chondroitin Sulfate Oligosaccharides--
The CS
polysaccharides (20-100 mg) in 2-10 ml of 100 mM sodium
acetate, 150 mM sodium chloride, pH 5.0, were treated with ovine testicular hyaluronidase (1000-5000 units) and incubated at
37 °C for 2 h (55). The enzyme digests were heated in a boiling water bath for 5 min, and 1-ml aliquots corresponding to 10 mg of
polysaccharide chromatographed on Bio-Gel P-6 columns (1.5 × 70 cm) in 100 mM pyridine, 100 mM acetic acid, pH
5.4. Fractions of 2 ml were collected and aliquots analyzed for
oligosaccharide content by the carbazole method (58).
Oligosaccharide-containing fractions were separately pooled,
lyophilized, and analyzed by polyacrylamide gel electrophoresis. Prior
to lyophilization, tetrasaccharide-containing fractions were desalted
on Bio-Gel P-2 columns (1.5 × 75 cm) in 100 mM
pyridine, 100 mM acetic acid, pH 5.4.
Polyacrylamide Gel Electrophoresis of C4S
Oligosaccharides--
Aliquots containing 3-4 µg of CS
oligosaccharides obtained by Bio-Gel P-6 chromatography or 30-50 µg
of total digests were dissolved in 100 mM Tris base, 100 mM boric acid, 2 mM EDTA, pH 8.3, containing 2 M sucrose; 0.2% bromphenol blue in the above buffer was
used as tracking dye. The solutions were electrophoresed on
1.5-mm-thick 10% polyacrylamide gels (14 × 23.5 cm) in 100 mM Tris base, 100 mM boric acid, 2 mM EDTA, pH 8.3 (55). The gels were stained with 0.3%
Alcian blue in 3% aqueous acetic acid containing 50 mM
MgCl2 for 4 h, and destained with the same solution (59). The gels were further stained with ammoniacal silver (60). Briefly, gels were treated with 10% glutaraldehyde for 30 min, washed three times with water for 30 min. The gels were treated with
ammoniacal silver, washed two times with water for 30 s, and then
developed with 0.005% citric acid and 0.019% formaldehyde and washed
with water.
Solvolytic Desulfation of Glycosaminoglycans--
The sodium
salt of sturgeon notochord C4S (20 mg) was converted into free acid
using Dowex 50W-X8 (H+), neutralized with pyridine, and
lyophilized (61). The pyridinium salt of C4S was dissolved in 10 ml of
10% aqueous Me2SO, divided into 10 equal parts, and placed
in separate screw-capped glass vials. The vials were heated at
80 °C, and each was removed at 5, 15, 30, 45, 60, 75, 90, 105, 120, and 140 min and cooled in an ice bath. The reaction mixture in each
vial was diluted to 2 ml with water, the pH adjusted to 9.0 with 0.1 M NaOH, dialyzed (molecular weight cut-off 3,500) against
water, and lyophilized. Experiments were repeated several times with
slightly altered time periods to obtain C4Ss with sulfate contents
ranging from 3% to 89% (see Table II).
Regioselective 6-O-Desulfation of GAGs--
C4Ss from bovine
trachea and whale cartilage (100 mg each) were separately desalted on
Dowex 50W-X8 (H+), converted into the pyridinium salts,
lyophilized, and dissolved in dry pyridine (20 ml).
N,O-Bis(trimethylsilyl)acetamide (4 ml) was added
to a final concentration of 20% and heated in a screw-capped glass
tube at 80 °C for 4 h (62). The reaction mixtures were cooled
in an ice bath, and ice-cold water (25 ml) was added to decompose
excess sialylating reagent, dialyzed against water, and lyophilized.
Enzymatic Digestion of GAG Chains--
For disaccharide
compositional analysis, GAGs (40-50 µg each) were digested with
chondroitinase ABC (20 milliunits) in 50 µl of 100 mM
Tris-HCl, pH 8.0, containing 30 mM NaOAc and 0.01% BSA at
37 °C for 5 h (54).
Disaccharide Composition Analysis of GAG Chains--
The
disaccharides released by the chondroitinase ABC digestion of CS or
DS were analyzed on a 4.6 × 250-mm amine-bonded silica PA03
column (YMC Inc., Milford, MA) using 600E HPLC system (Waters, Milford,
MA) as described (63). The enzyme digests corresponding to 10-15 µg
of GAGs were injected and eluted with a linear gradient of 16-530
mM NaH2PO4 over 70 min at a flow
rate of 1 ml/min at room temperature. The elution of disaccharides was
monitored by measuring the absorption at 232 nm using a Waters 484 variable wavelength UV detector. The data were processed with the
Millennium 2010 chromatography manager using NEC PowerMate 433 data
processing system.
 |
RESULTS |
Specificity of P. falciparum-IRBC Adherence to the CS Chains of
Placental CSPGs--
In the preceding paper (24), we reported that the
unusually low sulfated CSPGs localized in the intervillous spaces of
human placenta mediate the in vivo adherence of IRBCs. In
this paper, we present the data that establishes the specificity of
IRBC adherence to the placental CSPGs and define structural
requirements for the adherence. In an in vitro cytoadherence
assay, when a mixture of infected and uninfected RBCs overlaid on
CSPG-coated plastic plates, only IRBCs but not RBCs bound to the CSPGs
of the placental intervillous spaces (data not shown). The adherence of
IRBCs was completely abolished upon prior treatment of the CSPG-coated
plates with chondroitinase ABC or testicular hyaluronidase; the binding was not affected when the plates were treated with heparitinase or
S. hyalurolyticus hyaluronidase (data not shown). These
results clearly demonstrate that CS chains of the placental CSPGs
mediate the IRBC adherence. The structural requirement for IRBC
adherence to the placental CSPGs was studied by the inhibition of
cytoadherence using CSs from different sources, which contain variable
structural features (see below). In all the studies described here,
highly purified BCSPG-2 fraction (24) was used for the adherence assay.
Information on the level of 4-sulfation required for the optimal IRBC
binding and the effect of sulfate groups at other positions within C4S
chains is lacking. Because the CS chains of the CSPGs of the placental
intervillous spaces, BCSPG-1 and BCSPG-2, contain only ~2% and
~8% 4-sulfated groups, respectively (24), it is possible that the
IRBC adherence could be mediated by one or more factors such as unique
distribution of sulfate groups, unusual GAG structural features within
the chondroitin chain, or nonspecific charge interactions. To examine
these possibilities, a variety of GAGs including completely nonsulfated
chondroitin, HA, fully sulfated C4S, chondroitin sulfates with varying
amounts of 4-, 6-, and nonsulfated disaccharide repeats, CS chains that
contain significant levels of 2,6- and 4,6-disulfated disaccharide
repeats (C2,6diS and C4,6diS), DS, and heparin were analyzed for their compositions and ability to inhibit IRBC adherence (Table
I, Fig. 1).
Whereas all variously 4-sulfated CSs inhibited IRBC adherence, albeit
to different degrees (see below), nonsulfated chondroitin, HA, C6S,
C2,6diS, and heparin were completely non-inhibitory (Fig. 1). Highly
sulfated dextran sulfate, HS, and pentosan polysulfate were also
completely non-inhibitory (data not shown). These data indicated that
the IRBC adherence was not because of nonspecific interactions with the
strongly charged anionic sulfate groups but is mediated by a specific
4-sulfated chondroitin structure. Lack of inhibition by HA and HS
suggest that the activity was not due to low levels of other GAG
structural features within C4S chains. The inhibitory activity
exhibited by DS from porcine intestinal mucosa was comparable to that
of the fully 4-sulfated CS from sturgeon notochord, and it is likely
because of the presence of significant amounts of C4S structural
features in the DS chains. The complete inactivity of C2,6diS in
contrast to the efficient inhibition by C4,6diS was interesting
considering that both GAGs contain similar levels of 4-sulfated
disaccharide units. A comparison of the structural differences between
these two GAGs (Table I) suggests that C-2 hydroxyl of GlcA should be
free for interaction with IRBCs. The efficient inhibition of IRBC
adherence to BCSPG-2 by C4,6diS demonstrates that the presence of high
levels of 6-sulfate groups in addition to 4-sulfate groups has no
significant effect on IRBC binding.
View this table:
[in this window]
[in a new window]
|
Table I
Disaccharide composition of commercially available GAGs used for
inhibition of IRBC binding to CSPG of human placental intervillous
spaces
The GAGs were digested with chondroitinase ABC, and the disaccharides
formed were analyzed by HPLC as described under "Experimental
Procedures."
|
|

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Inhibition of IRBC binding to the placental
CSPG by GAGs. The plastic Petri dishes were coated with 0.2 µg/ml solution of CSPG from human placenta (BCSPG-2 fraction, see
Ref. 24) in PBS, pH 7.2, and blocked with BSA. A 2% suspension of
IRBCs in PBS, pH 7.2, was pre-incubated with various GAGs at the
indicated concentrations for 30 min at room temperature and overlaid on
the CSPG-coated plates. After a 40-min incubation at room
temperature, the unbound cells were washed, the bound cells were fixed,
stained with Giemsa, and measured using light microscopy. , bovine
trachea C4S; , whale cartilage C4S; , sturgeon notochord C4S;
, DS; , C6S; , C2,6diS; , C4,6diS; , chondroitin; ,
heparin; ×, hyaluronic acid. The plotted values represent the
average of at least three different experiments each performed in
duplicate. Standard deviations in all IRBC inhibition assays are
generally ±5%, and these are not shown in figures to avoid
overlapping.
|
|
Inhibition of IRBC Adherence to Placental CSPG by C4Ss with Varying
Sulfation Pattern--
Many CSs that are classified as C4S contain
variable amounts of 6-sulfate groups, and they differ significantly
with respect to the levels of 4-sulfate groups, and thus they are
likely to differ in the distribution of sulfate groups within their
repeating disaccharide units (see Table I). To investigate how these
varying structural elements within C4S chain contribute to IRBC
adherence, three distinctly different C4Ss, almost fully 4-sulfated C4S
from sturgeon notochord, C4S from whale cartilage with 69%, 27%, and 4% of the disaccharide repeats, respectively, 4-, 6-, and nonsulfated, and C4S from bovine trachea with 53%, 39% and 8%, respectively, 4-, 6-, and nonsulfated, were studied for their ability to inhibit IRBC
binding to the placental CSPG (Fig. 1). Although the C4S chains from
all the three sources inhibited IRBC binding in a dose-dependent manner, contrary to the expected results,
the completely 4-sulfated C4S was about 2.5 times less efficient in
inhibiting IRBC binding compared with the C4Ss from the whale cartilage
and bovine trachea (Fig. 1). This is despite the presence of
significant amounts of 6-sulfation in whale cartilage and bovine
trachea C4Ss. These results suggest that the C4S structures containing
both 4-sulfated and 4-nonsulfated disaccharide repeats support
efficient IRBC binding. C6S was completely non-inhibitory even at >100
µg/ml, suggesting that 6-O-sulfation does not contribute
to IRBC adherence. This conclusion agrees with the unaltered inhibitory
activities of C4Ss from bovine trachea and whale cartilage after the
regioselective removal of sulfate groups at C-6 (see below).
Inhibition of IRBC Adherence to Placental CSPG by Partially
Desulfated CS--
To study further the requirements of 4-sulfated and
4-nonsulfated disaccharide repeats within the CS chains for effective interaction with IRBCs, we prepared CSs containing various levels of
4-sulfate groups, by solvolytic desulfation of the sturgeon notochord
C4S or regioselective 6-O-desulfation of whale cartilage and
bovine trachea C4Ss (Table II). The
inhibitory capacities of these partially desulfated C4Ss were assessed
(Fig. 2 and data not shown). Although all
C4Ss competitively inhibited IRBC adherence to the placental CSPG, they
differed significantly in their inhibitory activity. At similar
concentrations, the C4Ss containing 30-80% sulfated disaccharides and
20-70% nonsulfated disaccharides had the higher inhibitory capacity
compared with the fully 4-sulfated sturgeon notochord C4S (Fig. 2). The
inhibitory ability of C4Ss that contain 70% and 30%, 4-sulfated and
nonsulfated disaccharide repeats, respectively, prepared from sturgeon
notochord C4S was comparable to that of the untreated whale cartilage
C4S (compare Fig. 1 with Fig. 2). Similarly, C4S from bovine trachea
showed a comparable level of inhibition with that of the partially
desulfated sturgeon notochord C4S with 52% 4-sulfated disaccharides
(compare Fig. 1 with Fig. 2). Furthermore, the inhibitory capacities of these partially 4-sulfated CSs, BTC4S-46 and WCC4S-65, obtained from
regioselective 6-O-desulfation of bovine trachea and whale cartilage C4Ss, respectively (Table II and Fig. 2), were comparable to
that of partially desulfated SNC4S with similar 4-sulfate contents (not
shown). These results confirm that sulfate groups at 6-O position of GalNAc of whale cartilage and bovine trachea C4S chains neither interact nor interfere with the IRBC binding.
View this table:
[in this window]
[in a new window]
|
Table II
Disaccharide composition of intact and partially desulfated C4Ss
The variously sulfated C4Ss were digested with chondroitinase ABC and
the disaccharides formed were analyzed by HPLC as described under
"Experimental Procedures."
|
|

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 2.
Inhibition of IRBC adherence to placental
CSPG by partially desulfated C4S. The inhibition of IRBC adhesion
to BCSPG-2 by the partially desulfated C4Ss was performed as described
in legend to Fig. 1. , BTC4S-46; , SNC4S-3; , SNC4S-11; ×,
SNC4S-30; , SNC4S-38; , SNC4S-52; , SNC4S-60; , SNC4S-78;
, SNC4S-89; +, SNC4S-98. SNC4S, BTC4S, and WCC4S refer to C4Ss from
sturgeon notochord, bovine trachea, and whale cartilage, respectively.
The numbers that follow the hyphen refer to the percentage of 4-sulfate
contents. The inhibition of IRBC adherence by SNC4S-8, SNC4S-18, and
WCC4S-65 (see Table II) was also assessed.
|
|
Of the various partially desulfated CSs prepared by the solvolytic
desulfation of sturgeon notochord C4S (Table II), those containing
30-50% sulfated and 50-70% nonsulfated disaccharide repeats showed
maximum inhibition of IRBC adherence to the placental CSPG (Fig. 2).
Although the 4-sulfated disaccharide content in the CS chains of the
placental CSPGs (BCSPG-1 and BCSPG-2) is 2% and 8% of the total (24),
C4Ss containing comparable or even up to 18% 4-sulfation in the
partially desulfated C4S were significantly less inhibitory.
Minimum C4S Structural Motif Involved in IRBC Adherence to
Placental CSPG--
To determine the minimum structural motif of the
C4S chain involved in the IRBC adherence, we prepared oligosaccharides
of varying sizes by partial enzymatic depolymerization of several C4Ss
with varying levels of 4-sulfation. In preliminary experiments, whale
cartilage C4S was partially depolymerized by treating with different
amounts of ovine testicular hyaluronidase for varying time periods
(64). The enzyme degraded ~40-50-kDa C4S (>100 disaccharide
repeating units) into a mixture of low molecular mass oligosaccharides.
Based on the results of these pilot experiments (64), optimal
conditions for the conversion of polysaccharides to maximum levels of
oligosaccharides with 2-20 repeating units were selected. Large
quantities of sturgeon notochord, bovine trachea, and whale cartilage
C4Ss were depolymerized, and the oligosaccharides were
size-fractionated on Bio-Gel P-6 columns. Each column fraction was
analyzed by polyacrylamide gel electrophoresis (Fig.
3), and oligosaccharides that are
homogeneous in size containing 2-7 disaccharide repeats as well as
non-homogeneous higher oligomers were analyzed for their ability to
inhibit IRBC adherence to the placental CSPG (Fig.
4 and data not shown). The
oligosaccharides with 3 or more disaccharide repeats, irrespective of
the C4S used for their preparation, were able to inhibit IRBC adherence
in a dose dependent manner. At comparable concentrations, inhibition by
C4S oligosaccharides was proportional to their chain lengths. Among
various sized oligosaccharides obtained from different C4Ss, only the
dodecasaccharides and higher oligomers (with six or more disaccharide
repeats) inhibited IRBC adherence to the extents comparable to that of
the corresponding intact C4S polymers at all concentrations tested
including that required for complete inhibition (Fig. 4). In the case
of bovine and whale C4S, the decasaccharides exhibited about 75-85%
activity of the intact polymer in a dose-dependent manner,
whereas the decasaccharides from sturgeon notochord showed 50-60% of
activity compared with the corresponding intact C4S. The octa- and
hexasaccharides showed significantly lower inhibitory activities, and
the tetrasaccharides showed low level of activity only at high
concentrations (>100 µg/ml). As in the case of intact GAGs, the
oligosaccharides obtained from fully 4-sulfated C4S from sturgeon
notochord were 2-3-fold less efficient compared with those from whale
cartilage and bovine trachea C4S (Fig. 4). A comparison of the
inhibition of IRBC binding to the placental CSPG by dodecasaccharides
prepared from different C4Ss with the respective intact polysaccharides
(Fig. 4) clearly indicates that, in each case, the dodecasaccharide
inhibited the IRBC adherence to the same level as that of the
corresponding polysaccharide. Thus, the minimum CS chain motif required
for efficient interaction of IRBCs is a dodecasaccharide.

View larger version (106K):
[in this window]
[in a new window]
|
Fig. 3.
Polyacrylamide gel electrophoresis of C4S
oligosaccharides from Bio-Gel P-6 column fractions. C4S from
bovine trachea was digested with ovine testicular hyaluronidase and
chromatographed on Bio-Gel P-6 column (1.5 × 70 cm) as described
under "Experimental Procedures." Fractions were lyophilized and
dissolved in water, and aliquots corresponding to 3-4 µg of
oligosaccharide were electrophoresed on a 1.5-mm-thick 10%
polyacrylamide gel (14 × 23.5 cm), stained successively with
Alcian Blue and ammoniacal silver, and photographed. The Bio-Gel P-6
column fraction numbers are indicated at the bottom, and the
oligosaccharide size (number of disaccharide repeats) are indicated to
the left. Oligosaccharides from C4Ss from whale cartilage
and sturgeon notochord were similarly prepared.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 4.
Inhibition of IRBC binding to the placental
CSPG by C4S oligosaccharides. The inhibition of IRBC adhesion to
BCSPG-2 by the oligosaccharides purified on Bio-Gel P-6 column was
performed as described in Fig. 1. A-C, oligosaccharides
from bovine trachea C4S, sturgeon notochord C4S, and whale cartilage
C4S, respectively. , tetrasaccharide; , hexasaccharide; ,
octasaccharide; , decasaccharide; , dodecasaccharide; ,
tetradecasaccharide; ×, polysaccharide.
|
|
Inhibition of IRBC Adherence to Placental CSPG by Differentially
4-Sulfated C4S Dodecasaccharides--
To determine the extent of
4-sulfation required for efficient interaction of the CS
dodecasaccharide motif with IRBCs, we partially depolymerized C4Ss
containing various levels of 4-sulfate groups using testicular
hyaluronidase. From each enzymatic digest, dodecasaccharides were
isolated by gel filtration on Bio-Gel P-6 column. The disaccharide
composition of these oligosaccharides, determined by HPLC after
digestion with chondroitinase ABC (Table III), were generally comparable to those
present in corresponding C4Ss. The dodecasaccharides were tested for
their ability to inhibit IRBC binding to the placental CSPG (Fig.
5). Oligosaccharides with two or three
sulfate groups per molecule inhibited IRBC adherence to the placental
CSPG to significantly higher level when compared with those with either
more than three or less than two sulfate groups. These results together
with the chain length requirement for binding indicate that the minimum
CS structural motif for the adherence of IRBCs by C4S chains is a
dodecasaccharide with two or three 4-sulfate groups.
View this table:
[in this window]
[in a new window]
|
Table III
Disaccharide composition of partially desulfated dodecasaccharides
The dodecasaccharides (DDSs) with varying 4-sulfate contents were
prepared by partial depolymerization of the variously 4-sulfated C4Ss
from sturgeon notochord (see Table II) with testicular hyaluronidase
and Bio-Gel P-6 chromatography as described under "Experimental
Procedures." The DDSs were digested with chondroitinase ABC and the
disaccharides formed were analyzed by HPLC.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
Inhibition of the IRBC binding by variously
sulfated C4S dodecasaccharides. The inhibition of IRBC adhesion to
BCSPG-2 by C4S dodecasaccharides (see Table III) prepared from
partially desulfated sturgeon notochord C4Ss was carried out at 5 µg/ml as described in Fig. 1. The numbers on the
x axis indicate the percentage sulfate content of
the dodecasaccharides.
|
|
 |
DISCUSSION |
In the preceding paper (24), we reported the detailed
structural characterization of various CSPGs purified from different regions of human placenta, and identified the CSPGs responsible for the
accumulation of P. falciparum-IRBCs in the intervillous spaces of the placenta. In this study, we demonstrate that the binding
of IRBCs to the placental CSPGs is CS chain-specific, and using these
CSPGs (natural receptors) in a cytoadherence assay, we defined the key
structural elements and minimum CS chain length required for effective
IRBC binding. The important findings are as follows. 1) The C4S chains,
in which all the disaccharide repeats are 4-sulfated, were
significantly less efficient in binding IRBCs compared with C4S
containing both sulfated and nonsulfated disaccharide units. 2) C4S
chains with 1:1 to 1:2 ratios of 4-sulfated and nonsulfated
disaccharide repeats effectively bind IRBCs. 3) Significant levels (up
to 40%) of 6-sulfation within C4S have no detectable effect on the
adherence capacity of the C4S chains. 4) The minimum C4S chain length
required for optimal IRBC binding is a dodecasaccharide with two or
three sulfate groups.
The results presented in this paper indicate that IRBC adherence to the
CSPGs of placental intervillous spaces is mediated by low sulfated CS
chains with a stringent specificity for 4-sulfation. The data also
indicate that IRBC adherence is not due to either the presence of low
levels of other GAG structural features in the CSPGs or nonspecific
anionic charge interactions by the sulfate groups. Several lines of
evidence support these conclusions. First, the binding of IRBCs to the
placental CSPG is completely abolished when the coated plates were
treated with CS-degrading enzymes but not when treated with DS- or
HS-degrading enzymes; the enzyme that specifically degrade HA also has
no effect. Second, only C4S but not C6S, the closely related GAG that
differs only in the position of sulfate substitution, can inhibit IRBC
adherence. Completely nonsulfated chondroitin chains, hyaluronic acid,
and highly sulfated GAGs such as heparin, C2,6diS, dextran sulfate, and
pentosan polysulfate were all non-inhibitory. Thus, these data are
consistent with the results of previous studies, which reported that
the adherence of IRBCs to the placenta is mediated specifically by C4S
(12-14).
Although previous studies have shown that the adherence of IRBCs to
human placenta is mediated by C4S, the details of the structural
requirements, particularly with respect to the levels and the
distribution of sulfate groups within the CS chains have not been
reported. The data presented in this paper show that fully sulfated C4S
from sturgeon notochord was markedly less active in inhibiting IRBC
adherence to the placental CSPG compared with C4S containing
significant levels of nonsulfated disaccharide repeats. Of the several
CSs with varying levels of 4-sulfated disaccharide repeats tested,
those in which 30-50% of the disaccharide repeats with 4-sulfated and
the remainder 4-nonsulfated showed maximum inhibition. C4S containing
18% of 4-sulfated disaccharide repeats had the similar levels of
inhibitory capacity as those exhibited by C4S with 60% sulfate
content, and those with 3% and 8% 4-sulfated disaccharide
repeats showed only marginal inhibition. This is surprising
considering the low levels of sulfation in the CS chains of placental
CSPGs. One explanation for these results is that the 4-sulfated
disaccharide repeats in the CS chains of placental CSPGs are clustered
such that some locations within the CS chains contain optimal
distributions of 4-sulfated and 4-nonsulfated disaccharide repeats.
Alternatively, it is possible that the structural requirement for IRBC
binding with respect to the level of 4-sulfation is different from that
required for effective inhibition.
Two naturally occurring C4Ss, one from bovine trachea and the other
from whale cartilage, which are 53% and 69%, respectively, 4-sulfated
with the major portions of the remainder 6-sulfated efficiently
inhibited IRBC adherence to the placental CSPG. Since the CS chains of
placental CSPGs lack 6-sulfation, these results together with the
superior inhibitory ability of C4S from bovine trachea suggest that the
primary hydroxyl group of the GalNAc is not interacting significantly
with IRBCs. Consistent with this conclusion, the inhibitory
abilities of C4Ss from bovine trachea and whale cartilage were
unaltered after the selective removal of the majority of the 6-sulfate
groups by regiospecific 6-O-desulfation. This conclusion is
further supported by the observation that a highly sulfated C4,6diS
containing 60%, 21%, 10%, and 9%, respectively, 4,6-di-, 4-, 6-sulfated, and nonsulfated disaccharide repeats showed ~2-fold
better inhibitory capacity compared with the fully 4-sulfated CS.
This study conclusively establishes that the minimum CS chain length
required for effective inhibition of IRBC binding to the placental
CSPG, at levels similar to those exhibited by the intact C4S
polysaccharides, is a dodecasaccharide. Among the series of
oligosaccharides of varying sizes prepared by the partial enzymatic digestion of three different naturally occurring C4Ss (from sturgeon notochord, bovine trachea, and whale cartilage) containing different levels of 4-sulfation, in all cases, oligosaccharides with more than
three disaccharide repeats inhibited IRBC binding in a
dose-dependent manner. The level of inhibition was directly
proportional to the oligosaccharide size. In each case, only
dodecasaccharide or higher oligomers inhibited IRBC binding to the
similar levels as those of the corresponding intact C4Ss at comparable
concentrations. As in the case of intact C4Ss, inhibition by
dodecasaccharide, in which all six disaccharide repeats are 4-sulfated,
was markedly less compared with the dodecasaccharides containing both
4-sulfated and 4-nonsulfated disaccharides. Of the variously 4-sulfated
dodecasaccharides studied, oligosaccharides containing two or three
sulfate groups maximally inhibited IRBC binding compared with the same
size oligosaccharides with less than two or more than three sulfate
groups. Since oligosaccharides studied are likely to contain a mixed
population with varying, albeit in a narrow range, number of sulfate
groups, it is not possible to define the exact number and the precise
distribution within the six disaccharide repeats. Because, naturally
occurring GAGs are highly heterogeneous with respect to the
distribution of sulfate groups, the fractionation of oligosaccharides
of this size, based on the positions of sulfate distribution, is hard to achieve. However, chemically synthesized oligosaccharides with sulfate groups at defined positions should identify the precise structural requirements for the maximal inhibition of IRBC adherence.
Previously, four different studies including the one of our own
reported contradictory information on the minimum CS chain length
requirement for IRBC adherence (48-50, 64). Using recombinant thrombomodulin in an in vitro cytoadherence assay, Beeson
et al. (48) assessed the inhibition by oligosaccharide
fractions with 1-10 disaccharide repeats prepared from bovine trachea
C4S, and found that the minimum structural motif that supports the IRBC adherence was a tetradecasaccharide. In that study, inhibition by
dodecasaccharides and decasaccharides were, respectively, ~60% and
~30% of that of the intact C4S. A second study assayed C4S oligosaccharides of molecular mass ranging from 1 to 9 kDa for inhibition of IRBC binding to in vitro cultured
Saimiri brain microvascular endothelial cells (49). In this
study, only oligosaccharides with size >4 kDa (with 8 or 9 disaccharide repeats) showed noticeable inhibitory activity and a 9-kDa
polysaccharide (~18 or 19 disaccharide repeats) was required for
inhibition equivalent to that by intact C4S. These two studies used
chondroitinase ABC, a lyase enzyme that forms an unsaturated
uronic acid at the nonreducing end for the preparation of CS
oligosaccharides. This might have rendered the nonreducing end of the
disaccharide repeat unable to interact with IRBCs because of altered
structural feature. In addition, the above studies used nonrelevant
receptors for the assessment of oligosaccharide inhibitory activity. In
a preliminary study using mixtures from partial hydrolysates of a C4S
(64), we reported that oligosaccharides with >7 disaccharide
repeats effectively inhibit IRBC adhesion. However, this study, using
C4S oligosaccharides that are homogeneous in size with two to seven
disaccharide repeats and relevant CSPG, unequivocally establishes that
a dodecasaccharide is the minimum chain length required for optimal
IRBC adherence.
The minimum C4S chain length of six disaccharide repeats required for
efficient interactions with IRBCs appears to be too large for a binding
site of a protein. Usually, oligosaccharide- or polysaccharide-binding
clefts for proteins such as enzymes, antibodies, and lectins contain
1-4 sugar residues, if nonconformational determinants are involved.
Therefore, the involvement of a long saccharide segment in binding of
IRBCs by partially 4-sulfated CS strongly suggests the requirement of
either a specific structural sequence (arrangements of sulfated and
nonsulfated disaccharide repeats) for the binding event or a
conformational epitope. Since our results demonstrate that both
4-sulfated and nonsulfated disaccharide repeats in the ratios of 1:1 to
1:2 are required for efficient interaction with IRBCs, it appears that
a specific distribution pattern of the sulfate groups within the CS
chain is involved in the binding of IRBCs. Although various sulfate
distribution can also be accommodated in oligosaccharides with four or
five disaccharide repeats, the requirement of a minimum CS chain length of six disaccharide repeats for maximal activity suggests the involvement of a specific conformational structure as well. It is
likely that the required conformation is attainable only with a CS
chain length of six disaccharide repeats having a specific distribution
of 4-sulfated groups. The involvement of conformational epitopes formed
from extended oligosaccharide segments has been shown in binding of
antibodies or cell adhesion molecules to polysaccharides. For example,
antibodies against meningococcal group B
-2,8-linked sialic acid
polysaccharide recognize only oligosaccharides with >10 sugar
residues, which can assume the required helical conformation (65, 66).
Similarly, antibodies against type 14 pneumococcal capsular
polysaccharide and type B Haemophilus influenzae
polysaccharide bind conformational epitopes in extended oligosaccharide
segments (67); binding of neuronal cell adhesion molecule to polysialic acid also has been suggested to involve conformational determinants (68).
Alternatively, it is possible that the adherence of IRBCs to the
placental CSPG may involve simultaneous interactions by two or more
binding sites of parasite protein(s) with closely related specificity,
each interacting with a partially sulfated trisaccharide within the
contiguous CS chain. However, we believe this is less likely. In either
case, it appears that the limited number of sulfate residues present in
the CS chains of placental CSPG are closely spaced within the large
60-kDa CS chains so as to provide specific structural requirements for
the adherence of IRBCs.
The C4S dodecasaccharide chain length required for maximal
inhibition of IRBC adhesion to the placental CSPG parallels the heparin
dodecasaccharide requirement for the effective binding and infectivity
of C. trachomatis to the host cells (29), and HS
dodecasaccharide binding to tumor-derived angiomodulin (47). The
identical GAG chain length requirement by proteins expressed by three
entirely different organisms despite that they use entirely different
types of GAG chains for attachment, low sulfated CS chains by P. falciparum (24), highly sulfated heparin by C. trachomatis (29), and moderately sulfated HS chains by human carcinoma cell-derived angiomodulin is surprising (47). Although it is
premature to make a generalization based on these three known cases out
of a large number of microbial as well as animal protein-GAG
interactions, it is tempting to speculate that the structural motifs of
the GAG-binding proteins of various organisms might be evolutionarily
conserved. Furthermore, it is possible that the binding motifs that are
conserved among proteins of various organisms may recognize a
conformational epitope within the GAG chains, and a minimum of 12 sugar
residues are required for a conformational structure, irrespective of
the GAG type.
In this study, oligosaccharides prepared from C4Ss from other animal
sources rather than those from the placental CSPGs were used for the
cytoadherence inhibition assay. The data show that dodecasaccharides
from these C4Ss were able to inhibit the adherence up to 90% at >20
µg/ml concentrations. However, in the case of human placental CSPGs,
the CS chain motif that binds IRBCs may have an unique sulfate group
distribution pattern. The dodecasaccharides obtained from those regions
of the CS chains may interact optimally with the parasite ligand to
completely inhibit IRBC binding even at lower concentrations.
 |
ACKNOWLEDGEMENTS |
We thank Manonmani Venkatesan for
parasite culturing, Dr. Ramachandra S. Naik for help in maintaining
parasite cultures, and Dr. Vincent Hascall (Cleveland Clinic
Foundation) for suggestions and help in confirming the disaccharide
composition of the CS chains of CSPGs by fluorophore-assisted
carbohydrate electrophoresis.
 |
FOOTNOTES |
*
This work was supported by grants from the Burroughs
Wellcome Fund for New Initiatives in Malaria Research and by Grant
AI45086 from NIAID, National Institutes of Health.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of
Biochemistry and Molecular Biology, Georgetown University Medical
Center, 3900 Reservoir Rd., N.W., Washington, DC 20007. Tel.:
202-687-3840; Fax: 202-687-7186; E-mail:
gowda@bc.georgetown.edu.
Published, JBC Papers in Press, September 25, 2000, DOI 10.1074/jbc.M006399200
 |
ABBREVIATIONS |
The abbreviations used are:
C4S, chondroitin
4-sulfate;
IRBC, infected red blood cell;
HA, hyaluronic acid;
CS, chondroitin sulfate;
C6S, chondroitin 6-sulfate;
C4, 6diS, chondroitin
4,6-disulfate;
C2, 6diS, chondroitin 2,6-disulfate;
CSPG, chondroitin
sulfate proteoglycan;
DS, dermatan sulfate;
HS, heparan sulfate;
HSPG, heparan sulfate proteoglycan;
GAG, glycosaminoglycan;
PG, proteoglycan;
GalNAc, N-acetylgalactosamine;
GlcNAc, N-acetylglucosamine;
GlcA, glucuronic acid;
IdoUA, iduronic
acid;
BSA, bovine serum albumin;
PBS, phosphate-buffered saline.
 |
REFERENCES |
| 1.
|
Magowan, C.,
Wollish, W.,
Anderson, L.,
and Leech, J.
(1988)
J. Exp. Med.
168,
1307-1320
|
| 2.
|
Biggs, B. A.,
Anders, R. F.,
Dillon, H. E.,
Davern, K. M.,
Martin, M.,
Petersen, C.,
and Brown, G. V.
(1992)
J. Immunol.
149,
2047-2054
|
| 3.
|
Biggs, B. A.,
Gooze, L.,
Wycherley, K.,
Wollish, W.,
Southwell, B.,
Leech, J. H.,
and Brown, G. V.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
9171-9174
|
| 4.
|
Baruch, D. I.,
Pasloske, B. L.,
Singh, H. B.,
Bi, X.,
Ma, X. C.,
Feldman, M.,
Taraschi, T. F.,
and Howard, R. J.
(1995)
Cell
82,
77-87
|
| 5.
|
Su, X. Z.,
Heatwole, V. M.,
Wertheimer, S. P.,
Guinet, F.,
Herrfeldt, J. A.,
Peterson, D. S.,
Ravetch, J. A.,
and Wellems, T. E.
(1995)
Cell
82,
89-100
|
| 6.
|
Smith, J. D.,
Chitnis, C. E.,
Craig, A. G.,
Roberts, D. J.,
Hudson-Taylor, D. E.,
Peterson, D. S.,
Pinches, R.,
Newbold, C. I.,
and Miller, L. H.
(1995)
Cell
82,
101-110
|
| 7.
|
Borst, P.,
Bitter, W.,
McCulloch, R.,
Van Leeuwen, F.,
and Rudenko, G.
(1995)
Cell
82,
1-4
|
| 8.
|
Gardner, J. P.,
Pinches, R. A.,
Roberts, D. J.,
and Newbold, C. I.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
3503-3508
|
| 9.
|
Scherf, A.,
Hernandez-Rivas, R.,
Buffet, P.,
Bottius, E.,
Benatar, C.,
Pouvelle, B.,
Gysin, J.,
and Lanzer, M.
(1998)
EMBO J.
17,
5418-5426
|
| 10.
|
Reeder, J. C.,
Cowman, A. F.,
Davern, K. M.,
Beeson, J. G.,
Thompson, J. K.,
Rogerson, S. J.,
and Brown, G. V.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
5198-5202
|
| 11.
|
Buffet, P. A.,
Gamain, B.,
Scheildig, C.,
Baruch, D.,
Smith, J. D.,
Hernandez-Rivas, R.,
Pouvelle, B.,
Oishi, S.,
Fuzii, N.,
Fusai, T.,
Parzy, D.,
Miller, L. H.,
Gysin, J.,
and Scherf, A.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
12743-12748
|
| 12.
|
Fried, M.,
and Duffy, P. E.
(1996)
Science
272,
1502-1504
|
| 13.
|
Rogerson, S. J.,
and Brown, G. V.
(1997)
Parasitol. Today
134,
70-75
|
| 14.
|
Fried, M.,
and Duffy, P. E.
(1998)
J. Mol. Med.
76,
162-171
|
| 15.
|
Brabin, B. J.
(1983)
Bull. WHO
61,
1005-1016
|
| 16.
|
McGregor, I. A.,
Wilson, M. E.,
and Billewicz, W. Z.
(1983)
Trans. R. Soc. Trop. Med. Hyg.
77,
232-244
|
| 17.
|
Steketee, R. W.,
Wirima, J. J.,
Slutsker, L.,
Heymann, D. L.,
and Breman, J. G.
(1996)
Am. J. Trop. Med. Hyg.
55,
2-7
|
| 18.
|
Baruch, D. I.,
Gormely, J. A.,
Ma, C.,
Howard, R. J.,
and Pasloske, B. L.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
3497-3502
|
| 19.
|
Robert, C.,
Pouvelle, B.,
Meyer, P.,
Muanza, K.,
Fujioka, H.,
Aikawa, M.,
Scherf, A.,
and Gysin, J.
(1995)
Res. Immunol.
146,
383-393
|
| 20.
|
Pouvelle, B.,
Meyer, P.,
Robert, C.,
Bardel, L.,
and Gysin, J.
(1997)
Mol. Med.
3,
508-518
|
| 21.
|
Gysin, J.,
Pouvelle, B.,
Tonqueze, M. L.,
Edelman, L.,
and Boffa, M. C.
(1997)
Mol. Biochem. Parasitol.
88,
267-271
|
| 22.
|
Rogerson, S. J.,
Chaiyaroj, S. C.,
Ng, K.,
Reeder, J. C.,
and Brown, G. V.
(1995)
J. Exp. Med.
182,
15-20
|
| 23.
|
Chaiyaroj, S. C.,
Angkasekwinai, P.,
Buranakiti, A.,
Looareesuwan, S.,
Rogerson, S. J.,
and Brown, G. V.
(1996)
Am. J. Trop. Med. Hyg.
55,
76-80
|
| 24.
|
Achur, R. N.,
Valiyaveettil, M.,
Alkhalil, A.,
Ockenhouse, C. F.,
and Gowda, D. C.
(2000)
J. Biol. Chem.
275,
40344-40356
|
| 25.
|
Rostand, K. S.,
and Esko, J. D.
(1997)
Infect. Immun.
65,
1-8
|
| 26.
|
Wadström, T.,
and Ljungh, Ä.
(1999)
J. Med. Microbiol.
48,
223-233
|
| 27.
|
Herold, B. C.,
Gerber, S. I.,
Polonsky, T.,
Belval, B. J.,
Shaklee, P. N.,
and Holme, K.
(1995)
Virology
206,
1108-1116
|
| 28.
|
Banfield, B. W.,
Leduc, Y.,
Esford, L.,
Schubert, K.,
and Tufaro, F.
(1995)
J. Virol.
69,
3290-3298
|
| 29.
|
Chen, J. C.-R.,
Zhang, J. P.,
and Stephens, R. S.
(1996)
J. Biol. Chem.
271,
11134-11140
|
| 30.
|
Cooke, B. M.,
Rogerson, S. J.,
Brown, G. V.,
and Coppel, R. L.
(1996)
Blood
88,
4040-4044
|
| 31.
|
Bhavanandan, V. P.,
and Davidson, E. A.
(1992)
in
Glycoconjugates
(Allen, H. J.
, and Kissilus, E. C., eds)
, pp. 167-202, Marcel Dekker, Inc., New York
|
| 32.
|
Kjellen, L.,
and Lindahl, U.
(1991)
Annu. Rev. Biochem.
60,
443-475
|
| 33.
|
Poole, A. R.
(1986)
Biochem. J.
236,
1-14
|
| 34.
|
Fransson, L. A.
(1987)
Trends Biochem. Sci.
12,
406-411
|
| 35.
|
Ruoslahti, E.
(1989)
J. Biol. Chem.
264,
13369-13372
|
| 36.
|
Ruoslahti, E.
(1988)
Annu. Rev. Cell Biol.
4,
229-255
|
| 37.
|
San Antonio, J. D.,
Slover, J.,
Lawler, J.,
Karnovsky, M. J.,
and Lander, A. D.
(1993)
Biochemistry
32,
4746-4755
|
| 38.
|
Norgard-Sumnicht, K. E.,
Varki, N. M.,
and Varki, A.
(1993)
Science
261,
480-483
|
| 39.
|
Guimond, S.,
Maccarana, M.,
Olwin, B. B.,
Lindahl, U.,
and Rapraeger, A. C.
(1993)
J. Biol. Chem.
268,
23906-23914
|
| 40.
|
Maccarana, M.,
Casu, B.,
and Lindahl, U.
(1993)
J. Biol. Chem.
268,
23898-23905
|
| 41.
|
Najjam, S.,
Mulloy, B.,
Theze, J.,
Gordon, M.,
Gibbs, R.,
and Rider, C. C.
(1998)
Glycobiology
8,
509-516
|
| 42.
|
Schlessinger, J.,
Lax, I.,
and Lemmon, M.
(1995)
Cell
83,
357-360
|
| 43.
|
Saksela, O.,
Moscatelli, D.,
Sommer, A.,
and Rifkin, D. B.
(1988)
J. Cell Biol.
107,
743-751
|
| 44.
|
Vlodavsky, I.,
Bar-Shavit, R.,
Korner, G.,
and Fuks, G.
(1993)
in
Basement Membranes: Cellular and Molecular Aspects
(Rohrbach, D. H.
, and Tiple, R., eds)
, pp. 327-342, Academic Press, Orlando
|
| 45.
|
Koliakos, G. G.,
Kouzi-Koliakos, K.,
Furcht, L. T.,
Reger, L. A.,
and Tsilibary, E. C.
(1989)
J. Biol. Chem.
264,
2313-2323
|
| 46.
|
Maimone, M. M.,
and Tollefsen, D. M.
(1990)
J. Biol. Chem.
265,
18263-18271
|
| 47.
|
Kishibe, J.,
Yamada, S.,
Okada, Y.,
Sato, J.,
Ito, A.,
Miyazaki, K.,
and Sugahara, K.
(2000)
J. Biol. Chem.
275,
15321-15329
|
| 48.
|
Beeson, J. G.,
Chai, W.,
Rogerson, S. J.,
Lawson, A. M.,
and Brown, G. V.
(1998)
Infect. Immun.
66,
3397-3402
|
| 49.
|
Pouvelle, B.,
Fusaï, T.,
Lépolard, C.,
and Gysin, J.
(1998)
Infect. Immun.
66,
4950-4956
|
| 50.
| Fried, M., Lauder, R., and Duffy, P. E. (1998)
Glycobiology 8, Abstract 68
|
| 51.
|
Lambros, C.,
and Vanderberg, J. P.
(1979)
J. Parasitol.
65,
418-420
|
| 52.
|
Ockenhouse, C. F.,
Ho, M.,
Tandon, N. N.,
Van Seventor, G. A.,
Shaw, S.,
White, N. J.,
Jamieson, G. A.,
Chulay, J. D.,
and Webster, H. K.
(1991)
J. Infect. Dis.
164,
163-169
|
| 53.
|
Jensen, J. B.
(1978)
Am. J. Trop. Med. Hyg.
27,
1274-1276
|
| 54.
|
Oike, Y.,
Kimata, K.,
Shinomura, T.,
Nakazawa, K.,
and Suzuki, S.
(1980)
Biochem. J.
191,
193-207
|
| 55.
|
Cowman, M. K.,
Slahetka, M. F.,
Hittner, D. M.,
Kim, J.,
Forino, M.,
and Gadelrab, G.
(1984)
Biochem. J.
221,
707-716
|
| 56.
|
Hovingh, P.,
and Linker, A.
(1974)
Carbohydr. Res.
37,
181-192
|
| 57.
|
Hatae, Y.,
and Makita, A.
(1975)
Anal. Biochem.
64,
30-36
|
| 58.
|
Dische, Z.
(1947)
J. Biol. Chem.
167,
189-198
|
| 59.
|
Wall, R. S.,
and Gyi, T. J.
(1988)
Anal. Biochem.
175,
298-299
|
| 60.
|
Krueger, R. C., Jr.,
and Schwartz, N. B.
(1987)
Anal. Bochem.
167,
295-300
|
| 61.
|
Nagasawa, K.,
Inoue, Y.,
and Tokuyasu, T.
(1979)
J. Biochem.
86,
1323-1329
|
| 62.
|
Matsuo, M.,
Takano, R.,
Kamei-Hayashi, K.,
and Hara, S.
(1993)
Carbohydr. Res.
241,
209-215
|
| 63.
|
Sugahara, K.,
Shigeno, K.,
Masuda, M.,
Fujii, N.,
Kurosaka, A.,
and Takeda, K.
(1994)
Carbohydr. Res.
255,
145-163
|
| 64.
|
Gowda, D. C.,
and Ockenhouse, C. F.
(1999)
Biosci. Rep.
19,
261-271
|
| 65.
|
Hayrinen, J.,
Bitter-Suermann, D.,
and Finne, J.
(1989)
Mol. Immunol.
26,
523-529
|
| 66.
|
Brisson, J. R.,
Baumann, H.,
Imberty, A.,
Perez, S.,
and Jennings, H. J.
(1992)
Biochemistry
31,
4996-5004
|
| 67.
|
Wessels, M. R.,
and Kasper, D. L.
(1989)
J. Exp. Med.
169,
2121-2131
|
| 68.
|
Finne, J.,
and Makela, P. H.
(1985)
J. Biol. Chem.
260,
1265-1270
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit 